A Phase 2 interventional study of Eteplirsen in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 4 sites in 4 countries. Open to male participants aged 6 Months to 48 Months. Per ClinicalTrials.gov, last updated 2021-12-09.
Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 8th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 6 Months to 48 Months · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 1 started in 2017.
This study's enrollment of 15 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 2, and was the 10th registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and PK of once-weekly IV infusions of eteplirsen in approximately 12 male participants, ages 6 months to 48 months (inclusive), who have genotypically confirmed DMD with a deletion mutation amenable to exon 51 skipping.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.
Drug: Eteplirsen
Infusion for intravenous use.
Also known as: AVI-4658, EXONDYS 51®
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation From Study Drug
TEAEs were defined as adverse events (AEs) with an onset following administration of the first dose of study drug. An AE was any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the study drug. Abnormalities presented at Baseline were considered AEs if they reoccurred after resolution or worsen during the AE collection period. An SAE was defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
Time frame: Baseline up to Week 100
Number of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory Abnormality
Clinical laboratory parameters that were evaluated included * Any Grade ≥2 (moderate) or serious event without an alternative etiology that the Investigator deemed was related to study drug * Two consecutive drug-related serum creatinine levels ≥2\*upper limit of normal (ULN) without an alternative etiology * Creatine kinase (CK) levels \>50,000 units/liter (U/L) * A confirmed, unexplained, increase in gamma glutamyl transferase (GGT) \>3\*ULN and either an increase in bilirubin \>2\*ULN or nascent prothrombin time \>2\*ULN concurrently, without an alternative etiology
Time frame: Baseline up to Week 100
Number of Participants With at Least 1 Markedly Abnormal Vital Sign
The vital sign parameters that were evaluated included blood pressure, heart rate, respiration, and temperature. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
Time frame: Baseline up to Week 100
Abnormal Changes From Baseline or Worsening of Physical Examination Findings
Data not collected during the study for this Outcome Measure. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
Time frame: Baseline up to Week 100
Number of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO)
The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the centrally read ECG report were clinically significant. Clinical significance was defined as any variation in ECG findings that had medical relevance resulting in an alteration in medical care. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the ECHO report were clinically significant. Clinical significance was defined as any variation in ECHO findings that had medical relevance resulting in an alteration in medical care. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
Time frame: Weeks 8, 12, 24, 36, 48, 60, 72, 84, 96
Maximum Plasma Concentration (Cmax) of Eteplirsen
Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
Time to Reach Maximum Plasma Concentration (Tmax) of Eteplirsen
Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
Area Under Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Eteplirsen in Plasma
Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
Amount of Drug Eliminated in Urine
Amount of unchanged drug excreted in urine from time 0 to 4 hours after completion of dosing is reported.
Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
| Milestone | Eteplirsen |
|---|---|
| Started | 15 |
| Received at least 1 dose of study drug | 15 |
| Completed | 15 |
| Not completed | 0 |
TEAEs were defined as adverse events (AEs) with an onset following administration of the first dose of study drug. An AE was any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the study drug. Abnormalities presented at Baseline were considered AEs if they reoccurred after resolution or worsen during the AE collection period. An SAE was defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
| Participants | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| TEAE | 9 | 6 |
| SAE | 0 | 1 |
| AE leading to discontinuation from study drug | 0 | 0 |
Clinical laboratory parameters that were evaluated included * Any Grade ≥2 (moderate) or serious event without an alternative etiology that the Investigator deemed was related to study drug * Two consecutive drug-related serum creatinine levels ≥2\*upper limit of normal (ULN) without an alternative etiology * Creatine kinase (CK) levels \>50,000 units/liter (U/L) * A confirmed, unexplained, increase in gamma glutamyl transferase (GGT) \>3\*ULN and either an increase in bilirubin \>2\*ULN or nascent prothrombin time \>2\*ULN concurrently, without an alternative etiology
| Participants | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| Number of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory Abnormality | 9 | 6 |
The vital sign parameters that were evaluated included blood pressure, heart rate, respiration, and temperature. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
| Participants | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| Number of Participants With at Least 1 Markedly Abnormal Vital Sign | 9 | 6 |
Data not collected during the study for this Outcome Measure. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
No measurements were reported for this outcome.
The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the centrally read ECG report were clinically significant. Clinical significance was defined as any variation in ECG findings that had medical relevance resulting in an alteration in medical care. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the ECHO report were clinically significant. Clinical significance was defined as any variation in ECHO findings that had medical relevance resulting in an alteration in medical care. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.
| Participants | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| Number of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO) | 4 | 5 |
| microgram/milliliter (μg/mL) | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| Week 2 (2 mg/kg) | 9.67 ± 75.9 | 4.22 ± 120 |
| Week 6 (10 mg/kg) | 46.5 ± 72.3 | 17.2 ± 192 |
| Week 8 (20 mg/kg) | 63.3 ± 123 | 85.0 ± 67.6 |
| Week 10 (30 mg/kg) | 93.7 ± 55.5 | 63.8 ± 124 |
| Week 24 (30 mg/kg) | 78.2 ± 92.2 | 59.7 ± 82.7 |
| hours (hr) | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| 2 mg/kg (Week 2) | 0.58 (0.17 to 2.67) | 0.58 (0.42 to 0.67) |
| 10 mg/kg (Week 6) | 0.58 (0.47 to 4.25) | 0.72 (0.58 to 3.32) |
| 20 mg/kg (Week 8) | 0.78 (0.50 to 2.75) | 0.73 (0.53 to 1.17) |
| 30 mg/kg (Week 10) | 0.58 (0.50 to 1.48) | 0.92 (0.50 to 2.75) |
| 30 mg/kg (Week 24) | 0.63 (0.42 to 6.83) | 0.72 (0.58 to 1.83) |
| μg*hr/mL | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| 2 mg/kg (Week 2) | 13.8 ± 118 | 6.13 ± 73.1 |
| 10 mg/kg (Week 6) | 56.1 ± 57.2 | 27.8 ± 113 |
| 20 mg/kg (Week 8) | 92.1 ± 94.7 | 81.4 ± 89.6 |
| 30 mg/kg (Week 10) | 119 ± 30.8 | 85.0 ± 114 |
| 30 mg/kg (Week 24) | 100 ± 42.5 | 89.6 ± 43.8 |
Amount of unchanged drug excreted in urine from time 0 to 4 hours after completion of dosing is reported.
| μg | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| 2 mg/kg dose (Week 2) | 7720 ± 9060 | 1430 ± 1390 |
| 10 mg/kg (Week 6) | 56000 ± 73300 | 28700 ± 24100 |
| 20 mg/kg (Week 8) | 102000 ± 108000 | 65600 ± 47900 |
| 30 mg/kg (Week 10) | 263000 ± 209000 | 94700 ± 68500 |
| 30 mg/kg (Week 24) | 239000 ± 140000 | 147000 ± 132000 |
Collected over Baseline up to Week 100. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Age 24 to 48 Months | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Cohort 2: Age 6 to <24 Months | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| BronchiolitisInfections and infestations | 0/9 | 1/6 |
| Event | Cohort 1: Age 24 to 48 Months | Cohort 2: Age 6 to <24 Months |
|---|---|---|
| PyrexiaGeneral disorders | 7/9 | 6/6 |
| VomitingGastrointestinal disorders | 8/9 | 4/6 |
| NasopharyngitisInfections and infestations | 7/9 | 5/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/9 | 5/6 |
| RhinitisInfections and infestations | 4/9 | 4/6 |
| DiarrhoeaGastrointestinal disorders | 5/9 | 3/6 |
| FallInjury, poisoning and procedural complications | 5/9 | 2/6 |
| Head injuryInjury, poisoning and procedural complications | 5/9 | 2/6 |
| Ear infectionInfections and infestations | 3/9 | 3/6 |
| GastroenteritisInfections and infestations | 3/9 | 3/6 |
The Safety Set included all participants who were enrolled and received at least 1 dose of eteplirsen during the study.
| Age, Continuous(months) | Overall Study |
|---|---|
| Mean | 28.5 ± 12.94 |
| Age, Customized(Participants) | Overall Study |
|---|---|
| In utero | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 6 |
| Children (2-11 years) | 9 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65-84 years | 0 |
| 85 years and over | 0 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 0 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 8 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 9 |
| More than one race | 1 |
| Unknown or Not Reported | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Mar 2021, 42 months.
Results were first posted in Dec 2021, 8 months after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 42 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →